trial

A Study of Safety and Tolerability in Subjects With Schizophrenia

NCTId NCT01354353
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 75 (actual)
Sponsored by Denovo Biopharma LLC
Primary completion 2012-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
75 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2011-05
Primary completion
2012-03
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
PomaglumetadAripiprazole

Sponsors

Denovo Biopharma LLCLead Sponsor

Investigators

1
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)Study Director

Sites

2 total
Garden Grove, United StatesGlendale, United States

Facts & assertions

4 sourced
Enrollment
75
Phase
PHASE1
Primary Completion Date
2012-03
Status
COMPLETED
relationships
The graph out of here
drug
Pomaglumetad
drug
Aripiprazole
drug
lead_sponsor
Denovo Biopharma LLC
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST)
person